Trials / Completed
CompletedNCT06277752
A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)
A Randomized, Open-label,Single Dosing Clinical Trail to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128 in Chinese Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
A Phase I study to evaluate the pharmacokinetic/pharmacodynamic characteristics,safety and tolerability of IBI128 after multidosing in Chinese health subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dose-5 group | IBI128 300mg po. QD(Quaque Die) |
| DRUG | dose-1 group | IBI128 25mg po. QD(Quaque Die) |
| DRUG | dose-2 group | IBI128 50mg po. QD(Quaque Die) |
| DRUG | dose-4 group | IBI128 200mg po. QD(Quaque Die) |
| DRUG | dose-3 group | IBI128 100mg po. QD(Quaque Die) |
Timeline
- Start date
- 2024-03-05
- Primary completion
- 2024-03-16
- Completion
- 2024-03-16
- First posted
- 2024-02-26
- Last updated
- 2024-03-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06277752. Inclusion in this directory is not an endorsement.